Suzhou Connect Biopharmaceuticals, Ltd.
HomeحContact UsحSite Map
Connect Biopharma CEO Invited to Attend the CABS Investor Forum 2016 in San Francisco During the Week of the JP Morgan Healthcare Conference
Dr. Zheng Wei, Connect Biopharma CEO, is invited to attend the CABS Investor Forum 2016 during the JP Morgan Healthcare Conference (January 11-15, 2016) in San Francisco, California. The Forum, focusing on investment in drug innovation in China, was organized by the Chinese-American BioPharmaceutical Society, ChinaBio, Morrison & Foerster, will take place on January 13, 2016 in San Francisco. Dr. Zheng Wei will participate as a panelist.
About Suzhou Connect Biopharmaceuticals
Suzhou Connect Biopharma discovers and develops novel immune modulators for the treatment of autoimmune diseases and inflammation. The company identifies and advances its drug candidates through internal discovery and in-licensing. Its lead program CBP-307 is an orally-active S1P1 agonist with best-in-class potential for the treatment of a wide range of autoimmune disorders including inflammatory bowel disease (IBD), psoriasis, and multiple sclerosis (MS). In addition, the company is advancing CBP-174, an in-licensed drug candidate for allergic inflammation; and CBP-201, an internally discovered monoclonal antibody for the treatment of asthma, eczema and other inflammatory diseases.
Media Contact:
Rosemary Chang
Tel: 0512-53577866

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.